Heparin-induced thrombocytopenia future or investigational therapies: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Heparin-induced thrombocytopenia}}
{{Heparin-induced thrombocytopenia}}
{{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}}, Aric C. Hall, M.D., [mailto:achall@bidmc.harvard.edu]
{{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}}, Aric C. Hall, M.D., [mailto:achall@bidmc.harvard.edu], {{shyam}}


==Overview==
==Overview==

Latest revision as of 03:24, 31 July 2017

Heparin-induced thrombocytopenia

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Heparin-induced thrombocytopenia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Heparin-induced thrombocytopenia future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Heparin-induced thrombocytopenia future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Heparin-induced thrombocytopenia future or investigational therapies

CDC on Heparin-induced thrombocytopenia future or investigational therapies

Heparin-induced thrombocytopenia future or investigational therapies in the news

Blogs on Heparin-induced thrombocytopenia future or investigational therapies

Directions to Hospitals Treating Heparin-induced thrombocytopenia

Risk calculators and risk factors for Heparin-induced thrombocytopenia future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2], Aric C. Hall, M.D., [3], Shyam Patel [4]

Overview

Future therapies involve use of factor X inhibitors or direct thrombin inhibitors. The data is currently not mature enough to make any clinical recommendations.

Future or Investigational Therapies

Future therapies for HIT focus on use of new oral anticoagulants.[1] Director factor X inhibitors and newer direct thrombin inhibitors are being studied, but the data is currently in its infancy. Cost-effectiveness analyses will need to be done to determine whether it is appropriate to use these new agents.

References

  1. Harenberg J, Marx S, Krejczy M, Wehling M (2012). "New anticoagulants - promising and failed developments". Br J Pharmacol. 165 (2): 363–72. doi:10.1111/j.1476-5381.2011.01578.x. PMC 3268190. PMID 21740405.